Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Agios brings in $78mm through Series C; expands research scope

Executive Summary

Oncology biotech Agios Pharmaceuticals Inc. raised $78mm through its Series C round. Development partner Celgene participated, along with returning buyers Arch Venture Partners, Flagship Ventures, Third Rock Ventures, and three undisclosed large public investment funds. Celgene's COO Perry Karsen has joined the company's board. Agios will use the proceeds to continue developing its pipeline of cancer metabolism therapies, and will also expand its research into the field of genetic disorders, specifically inborn errors of metabolism.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies